Browse

Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent

DC Field Value Language
dc.contributor.authorKwak, Mi Kyung-
dc.contributor.authorHur, Keun-
dc.contributor.authorYu, Ji Eun-
dc.contributor.authorHan, Tae Su-
dc.contributor.authorKim, Woo Ho-
dc.contributor.authorSong, Soo-Chang-
dc.contributor.authorYang, Han-Kwang-
dc.contributor.authorLee, Sun Mi-
dc.contributor.authorYanagihara, Kazuyoshi-
dc.date.accessioned2012-05-31T06:43:43Z-
dc.date.available2012-05-31T06:43:43Z-
dc.date.issued2010-06-
dc.identifier.citationINVESTIGATIONAL NEW DRUGS; Vol.28 3; 284-290ko_KR
dc.identifier.issn0167-6997-
dc.identifier.urihttp://hdl.handle.net/10371/76693-
dc.description.abstractCurrent systemic chemotherapy in the treatment of solid tumors inevitably induces various systemic adverse effects. Locally injected chemotherapy is expected to overcome this limitation of systemic therapy. We evaluated by luminescence imaging the effects of chemotherapy administered locally by means of a biodegradable thermosensitive hydrogel polymer. The human gastric cancer cell line HSC44Luc was used for tumor induction, and it was confirmed to be sensitive to doxorubicin by MTT assay. Cells were injected subcutaneously into Balb/c-nude mice. When the mean volume of tumor reached 400 mm(3), we divided the mice into 6 groups (5 per group) according to treatment: 1) control (intratumor injection of PBS), 2) systemic injection of doxorubicin, 3) intratumor injection of polymer gel, 4) intratumor injection of polymer gel physically mixed with a low dose of doxorubicin, 5) intratumor injection of polymer gel physically mixed with a high dose of doxorubicin, 6) intratumor injection of conjugated polymer gel with doxorubicin. Body weight and tumor volume were measured every 2 or 3 days for 30 days after treatment. One mouse in each group was sacrificed for histopathologic examination every week. Reductions in body weight were not significantly different among groups. The relative rate of tumor growth was 774% in Group 1, 267% in Group 2, 813% in Group 3, -186% in Group 4, and 155% in Group 6, respectively. Thus the relative rate of tumor growth in the groups treated with polymer gel mixed with doxorubicin and the groups treated with conjugated polymer gel with doxorubicin were lower than that in the control group. Locally injectable chemotherapy using a thermosensitive hydrogel polymer with doxorubicin can suppress tumor growth effectively without severe systemic toxicity.ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subjectHydrogel polymerko_KR
dc.subjectCancer growthko_KR
dc.subjectBioluminescence imagingko_KR
dc.titleSuppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agentko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor곽미경-
dc.contributor.AlternativeAuthor허근-
dc.contributor.AlternativeAuthor유지은-
dc.contributor.AlternativeAuthor한태수-
dc.contributor.AlternativeAuthor김우호-
dc.contributor.AlternativeAuthor이선미-
dc.contributor.AlternativeAuthor송수창-
dc.contributor.AlternativeAuthor양한광-
dc.identifier.doi10.1007/s10637-009-9253-5-
dc.citation.journaltitleINVESTIGATIONAL NEW DRUGS-
dc.description.citedreferenceBilensoy E, 2008, INT J PHARM, V347, P163, DOI 10.1016/j.ijpharm.2007.06.051-
dc.description.citedreferenceZhang J, 2007, ACTA BIOMATER, V3, P838, DOI 10.1016/j.actbio.2007.05.011-
dc.description.citedreferenceChoi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003-
dc.description.citedreferenceRapoport N, 2007, PROG POLYM SCI, V32, P962, DOI 10.1016/j.progpolymsci.2007.05.009-
dc.description.citedreferenceAnkareddi I, 2007, INT J PHARM, V336, P241, DOI 10.1016/j.ijpharm.2006.11.065-
dc.description.citedreferenceKang GD, 2006, INT J PHARM, V319, P29, DOI 10.1016/j.ijpharm.2006.03.032-
dc.description.citedreferencePison U, 2006, EUR J PHARMACOL, V533, P341, DOI 10.1016/j.ejphar.2005.12.068-
dc.description.citedreferenceRamanan RMK, 2006, BIOTECHNOL PROGR, V22, P118, DOI 10.1021/bp0501367-
dc.description.citedreferenceCouffin-Hoarau AC, 2004, BIOMACROMOLECULES, V5, P2082, DOI 10.1021/bm0400527-
dc.description.citedreferenceRuel-Gariepy E, 2004, EUR J PHARM BIOPHARM, V57, P53, DOI 10.1016/S0939-6411(03)00095-X-
dc.description.citedreferenceJohn AE, 2003, FASEB J, V17, P2296, DOI 10.1096/fj.03-0166fje-
dc.description.citedreferenceSong SC, 2003, J CONTROL RELEASE, V90, P303, DOI 10.1016/S0168-3659(03)00199-8-
dc.description.citedreferenceShapiro CL, 2001, NEW ENGL J MED, V344, P1997-
dc.description.citedreferencePARTRIDGE AH, 2001, J NATL CANC I MONOGR, V30, P135-
dc.description.citedreferenceRATHI R, 2000-
dc.description.citedreferenceZENTNER GM, 1999, 9 INT S REC ADV DRUG-
dc.description.citedreferenceRATHI R, 1999-
dc.description.citedreferenceContag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523-
dc.description.citedreferenceJeong B, 1997, NATURE, V388, P860-
dc.description.citedreferenceCHA Y, 1997-
dc.description.citedreferenceLOWENTHAL RM, 1996, ONCOL CLIN N AM, V10, P967, DOI DOI 10.1016/S0889-8588(05)70378-6-
dc.description.citedreferenceKLEINSZANTO AJ, 1992, PROG CLIN BIOL RES, V374, P167-
dc.description.tc1-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse